Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2024-06, Vol.31 (6), p.3567-3568 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3568 |
|---|---|
| container_issue | 6 |
| container_start_page | 3567 |
| container_title | Annals of surgical oncology |
| container_volume | 31 |
| creator | Goense, Lucas van Hillegersberg, Richard |
| description | |
| doi_str_mv | 10.1245/s10434-024-15158-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2954777462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2954777462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-52dfebca9ae70c15f4e44e3f3350467f5eae64cbbc5485de47774d3d1f08ab733</originalsourceid><addsrcrecordid>eNp9kM9LwzAYhoMoTqf_gAcJePFSTZqk6bzIGPMHTB2iFy8hTb9uGf0xk3bif2-3TgUPnvKR73nfhAehE0ouaMjFpaeEMx6QkAdUUBEHbAcdUNFe8Simu-1MojgYhJHooUPvF4RQyYjYRz0WcyEpoQfobZgumpUua_xoV1XeFDrBtsRjXy3negY6xyNdGnD4w9ZzPK28re0K8DN4MLWtSvyg3cyW_goP8dRBoevGAZ6AXl4fob1M5x6Ot2cfvd6MX0Z3weTp9n40nASGSVIHIkwzSIweaJDEUJFx4BxYxpggPJKZAA0RN0liBI9FClxKyVOW0ozEOpGM9dF517t01XsDvlaF9QbyXJdQNV6FA7HJRGGLnv1BF1XjyvZ3qhVDZUSkWBeGHWVc5b2DTC2dLbT7VJSotXnVmVetebUxr9ah0211kxSQ_kS-VbcA6wDfrsoZuN-3_6n9AkvYjd0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3051760753</pqid></control><display><type>article</type><title>Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Goense, Lucas ; van Hillegersberg, Richard</creator><creatorcontrib>Goense, Lucas ; van Hillegersberg, Richard</creatorcontrib><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-024-15158-3</identifier><identifier>PMID: 38457101</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antineoplastic Agents, Immunological - therapeutic use ; ASO Perspectives ; Chemotherapy, Adjuvant ; Esophageal cancer ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - surgery ; Esophagectomy ; Humans ; Immunotherapy ; Margins of Excision ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Nivolumab - therapeutic use ; Oncology ; Prognosis ; Surgery ; Surgical Oncology ; Survival Rate ; Targeted cancer therapy</subject><ispartof>Annals of surgical oncology, 2024-06, Vol.31 (6), p.3567-3568</ispartof><rights>Society of Surgical Oncology 2024</rights><rights>Society of Surgical Oncology 2024.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c370t-52dfebca9ae70c15f4e44e3f3350467f5eae64cbbc5485de47774d3d1f08ab733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-024-15158-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-024-15158-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38457101$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goense, Lucas</creatorcontrib><creatorcontrib>van Hillegersberg, Richard</creatorcontrib><title>Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>ASO Perspectives</subject><subject>Chemotherapy, Adjuvant</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - surgery</subject><subject>Esophagectomy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Margins of Excision</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Nivolumab - therapeutic use</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Targeted cancer therapy</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9LwzAYhoMoTqf_gAcJePFSTZqk6bzIGPMHTB2iFy8hTb9uGf0xk3bif2-3TgUPnvKR73nfhAehE0ouaMjFpaeEMx6QkAdUUBEHbAcdUNFe8Simu-1MojgYhJHooUPvF4RQyYjYRz0WcyEpoQfobZgumpUua_xoV1XeFDrBtsRjXy3negY6xyNdGnD4w9ZzPK28re0K8DN4MLWtSvyg3cyW_goP8dRBoevGAZ6AXl4fob1M5x6Ot2cfvd6MX0Z3weTp9n40nASGSVIHIkwzSIweaJDEUJFx4BxYxpggPJKZAA0RN0liBI9FClxKyVOW0ozEOpGM9dF517t01XsDvlaF9QbyXJdQNV6FA7HJRGGLnv1BF1XjyvZ3qhVDZUSkWBeGHWVc5b2DTC2dLbT7VJSotXnVmVetebUxr9ah0211kxSQ_kS-VbcA6wDfrsoZuN-3_6n9AkvYjd0</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Goense, Lucas</creator><creator>van Hillegersberg, Richard</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20240601</creationdate><title>Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?</title><author>Goense, Lucas ; van Hillegersberg, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-52dfebca9ae70c15f4e44e3f3350467f5eae64cbbc5485de47774d3d1f08ab733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>ASO Perspectives</topic><topic>Chemotherapy, Adjuvant</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - surgery</topic><topic>Esophagectomy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Margins of Excision</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Nivolumab - therapeutic use</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goense, Lucas</creatorcontrib><creatorcontrib>van Hillegersberg, Richard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goense, Lucas</au><au>van Hillegersberg, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>31</volume><issue>6</issue><spage>3567</spage><epage>3568</epage><pages>3567-3568</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38457101</pmid><doi>10.1245/s10434-024-15158-3</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2024-06, Vol.31 (6), p.3567-3568 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2954777462 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Agents, Immunological - therapeutic use ASO Perspectives Chemotherapy, Adjuvant Esophageal cancer Esophageal Neoplasms - drug therapy Esophageal Neoplasms - pathology Esophageal Neoplasms - surgery Esophagectomy Humans Immunotherapy Margins of Excision Medicine Medicine & Public Health Monoclonal antibodies Nivolumab - therapeutic use Oncology Prognosis Surgery Surgical Oncology Survival Rate Targeted cancer therapy |
| title | Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T04%3A23%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20Nivolumab%20in%20Esophageal%20Cancer%20with%20Positive%20Resection%20Margins:%20A%20Premature%20Leap?&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Goense,%20Lucas&rft.date=2024-06-01&rft.volume=31&rft.issue=6&rft.spage=3567&rft.epage=3568&rft.pages=3567-3568&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-024-15158-3&rft_dat=%3Cproquest_cross%3E2954777462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3051760753&rft_id=info:pmid/38457101&rfr_iscdi=true |